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Introduction
Similar to many other Asian countries, breast conservation treatment (BCT) was relatively 
uncommon in Hong Kong until the late 1990s.1,2 Despite their smaller breast sizes and low 
percentage of mammographically detected lesions,3 the clinical and cosmetic outcomes 
of BCT in Hong Kong are quite comparable to those in many western series.4-6 Not 
surprisingly, Chinese women who underwent BCT were reported to have a significantly 
better perceptions of their body and sexual image than those who underwent modified 
radical mastectomy (MRM),7 but there were no differences in other aspects of measured 
quality of life.8 Probably related to the unpopularity of breast screening, low breast cancer 
awareness, misconception and other psychosocial factors,9-11 the BCT rate for T1-2 breast 
cancers in Hong Kong remains only around 22 to 30% in recent years.3,11 Nevertheless, a 
higher rate (39%) was observed in patients younger than 50 years.3
 Although many randomised trials have confirmed overall equivalent survival after 
	 Objective	 It	has	been	proposed	that	young	women	should	not	be	treated	
by	 breast	 conservation	 treatment	 because	 of	 a	 higher	 risk	 of	
local	 recurrences	 and	worse	 survival.	We	 therefore	 examined	
whether	breast	conservation	treatment	in	young	Chinese	women	
yielded	inferior	clinical	outcomes	compared	to	modified	radical	
mastectomy.
	 Design	 Retrospective	study.
	 Setting	 Clinical	 oncology	 department	 in	 a	 public	 hospital	 in	 Hong	
Kong.
	 Patients	 A	total	of	258	Chinese	women	with	invasive	breast	cancer,	aged	
below	 40	 years,	 and	 referred	 between	 January	 1994	 and	 July	
2006.
	 Results	 A	 total	 of	 124	 (48%)	 and	 134	 (52%)	 patients	 were	 treated	 by	
breast	conservation	treatment	and	modified	radical	mastectomy,	
respectively.	Mastectomy	patients	tended	to	have	larger	primary	
tumours	(P<0.001)	and	more	nodal	involvement	(P<0.001).	At	a	
median	follow-up	of	6.5	years,	there	was	no	significant	difference	
in	the	local	failure-free	survival	rate	(92%	vs	93%,	P=0.324)	and	
loco-regional	failure-free	survival	rate	(89%	vs	88%,	P=0.721)	in	
patients	having	breast	conservation	treatment	and	mastectomy.	
Probably	 due	 to	 their	 earlier	 presentation	 with	 disease,	 the	
former	 actually	 had	 better	 6-year	 distant	 failure-free	 survival	
(88%	vs	71%,	P=0.002)	and	overall	survival	(92%	vs	81%,	P=0.173)	
rates.	 Multivariate	 analyses	 showed	 that	 both	 the	 resection	
margin	status	(hazard	ratio=2.77,	P=0.050)	and	the	presence	of	
peritumoural	vascular	invasion	(hazard	ratio=3.01,	P=0.038)	were	
independent	 predictors	 of	 local	 recurrence;	 the	 nodal	 status	
(hazard	ratio=3.91,	P<0.001)	was	 the	only	predictive	 factor	 for	
overall	survival.	The	choice	of	breast	conservation	treatment	(vs	
modified	radical	mastectomy)	had	no	apparent	adverse	impact	
on	all	the	clinical	outcome	parameters	analysed.
	 Conclusion	 Breast	conservation	treatment	is	a	reasonable	option	for	many	
suitably	selected	young	Chinese	women.
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	 目的	 由於較高復發率及較低生存率，過往一直認為患有乳
癌的年輕女性不應接受保乳治療。本研究探討患有乳
癌的年輕女性中，接受保乳治療的與接受改良根治性
乳房切除術的比較，前者是否有較差的臨床結果。
	 設計	 回顧研究。
	 安排	 香港一所公營醫院的臨床腫瘤部門。
	 患者	 1994年1月至2006年7月期間，獲轉介的258名患有侵
犯性乳癌、40歲以下的華籍女性。
	 結果	 124名（48%）病人接受保乳治療，另134名（52%）
接受改良根治性乳房切除術。接受乳房切除術的病人
通常有較大的原發性腫瘤（P<0.001）及較多淋巴結
轉移（P<0.001）。中位數為6.5年的隨訪期間，保
乳治療及乳房切除術兩組病人在無局部復發生存率
（92%比93%；P=0.324）及無局部區域復發生存率
方面（89%比88%；P=0.721）皆沒有顯著差別。可
能由於接受保乳治療的病人大多於早期確診，她們的
6年無遠處轉移生存率（88% vs 71%；P=0.002）及
總生存率（92% vs 81%；P=0.173）較佳。多因素分
析顯示環周切緣情況（風險比=2.77；P=0.050）和
腫瘤周血管侵犯（風險比=3.01；P=0.038）是局部
復發的獨立預測因素。淋巴結轉移（風險比=3.91；
P<0.001）是總生存率的唯一預測因素。與改良根治
性乳房切除術比較，保乳治療於本研究的臨床結果並
無負面影響。
	 結論	 對於很多經篩選患有乳癌的年輕女性來說，保乳治療
是一個適切的選擇。
年輕是否患乳癌女性接受保乳治療的禁忌？
香港一所公營癌症治療中心的12年經驗
BCT or MRM,12,13 a higher local recurrence rate and 
worse survival in young women was often observed 
in BCT studies.6,14-16 Hence there was controversy 
as to whether the survival of young patients might 
be improved following MRM instead of BCT. Some 
international practice guidelines have also proposed 
that age of 35 years or younger should be a relative 
contra-indication for BCT.17 This proposed policy 
was particularly unwelcome in Asia, where there is 
a relatively high proportion of young breast cancer 
patients18 who understandably have the greatest 
desire for breast conservation.
 Accordingly we conducted a retrospective 
study to evaluate whether the clinical outcomes of 
young Chinese women treated by BCT have been 
compromised compared with those treated by MRM.
Methods
We retrospectively reviewed the medical records 
of all operated breast cancer patients referred 
to the Department of Clinical Oncology, Pamela 
Youde Nethersole Eastern Hospital, Hong Kong 
between January 1994 and July 2006. Breast surgeries 
were performed in our own hospital, other public 
hospitals, or private/overseas hospitals. All patients 
included in this study were Chinese women with T1-
2 (≤5 cm) breast cancers, aged below 40 years, and 
with no history of prior breast cancer or evidence of 
systemic failure within 3 months of surgery. Patients 
with unclear T classification, pure ductal carcinoma 
in situ (DCIS), DCIS with micro-invasion, pathological 
or clinical T3-4 breast cancers, and supraclavicular 
node secondaries at diagnosis were excluded from 
this study. Patients who were not primarily managed 
in this centre at initial diagnosis (ie referred at the 
time of relapse) were also excluded. Outcome data 
were updated in July 2008 before the final statistical 
analysis.
Treatment
All patients had definitive breast surgery performed, 
with or without induction chemotherapy to downsize 
the tumour. Wide local excision, quadrantectomy, 
and partial mastectomy were all considered as 
breast-conserving surgery. All patients with breast-
conserving surgery underwent postoperative whole 
breast irradiation as standard treatment. Wedged 
opposing tangential fields with 6 MV photons (linear 
accelerators) were used to deliver 50 Gy in 2-Gy daily 
fractions over 5 weeks. No bolus was used. Electron 
boost (9-12 MeV) to the tumour bed was given for 
patients with microscopic margins of less than 1 cm. 
The routine boost dose, prescribed at 90% isodose 
level, was 10 Gy in five daily fractions but a higher 
dose of 16 Gy in eight daily fractions was used if 
the microscopic margin was smaller than 1 mm. 
Post-mastectomy patients also received chest wall 
radiotherapy if their axillary nodes were involved, 
resection margins were close, or if the size of the 
invasive element was 4 cm or more. The technique was 
similar to that used in BCT, except that a bolus of 0.5 
cm was added to the chest wall and no further boost 
dose was given after 50 Gy. Regional radiotherapy 
covering the ipsilateral axilla and supraclavicular 
fossa was also offered to BCT or MRM patients with 
more than three positive axillary nodes or gross 
extranodal extension; a separate anterior field was 
used to deliver 50 Gy in 2-Gy daily fractions.
 Radiotherapy was started immediately after 
recovery from surgery, unless it had to be deferred 
until the completion of chemotherapy. Systemic 
adjuvant hormonal therapy and/or chemotherapy 
were added at the discretion of the attending 
clinicians.
Follow-up and reassessment
Patients had clinical examination by doctors every 2 
to 3 months in the first 2 years, every 4 to 6 months 
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in the third to fifth years, and annually thereafter. 
Annual bilateral mammograms with or without 
supplementary ultrasound examinations were also 
performed in patients with BCT.
Statistical methods
Chi squared and two-sided t tests were used to 
estimate the potential imbalance of clinical and 
pathological factors among patients treated by 
different surgical approaches. Survival analyses 
were performed with Kaplan-Meier estimates and 
Cox’s regression; forward stepwise selection was 
used in the multivariate Cox’s regression analyses. 
All statistical tests were performed at the 0.05 level 
of significance. The Statistical Package for the Social 
Sciences (Windows version 12.0; SPSS Inc, Chicago 
[IL], US) was used for all analyses.
Results
Between January 1994 and July 2006, 258 of all referred 
patients fulfilled the above selection criteria. Their 
mean age was 36 (range, 24-40) years. In all, 243 (94%) 
presented with breast lumps and only five (2%) had 
non-palpable lesions first detected by mammography 
or ultrasonography. Their breast surgeries were 
performed in our own hospital (67 patients, 26%), 
other public hospitals (68 patients, 26%), or local 
private/overseas hospitals (123 patients, 48%). 
Overall, 124 (48%) and 134 (52%) patients received 
BCT and MRM, respectively; 30 mastectomy patients 
also underwent immediate reconstructive surgery. 
Concerning the axillary surgical treatment, six 
patients refused axillary dissection; 14 had sentinel 
node biopsy only, and the remaining 238 underwent 
axillary dissection with or without preceding sentinel 
node sampling.
 Other demographic and clinical characteristics 
are shown in Table 1. Around a quarter of the patients 
had close or even positive resection margins, which 
was similar for those having BCT and MRM. The 
mastectomy patients tended to have larger primary 
tumours (P<0.001), more nodal involvement (P<0.001), 
more frequent use of neoadjuvant or adjuvant 
chemotherapy (P<0.001), and less frequent use of 
adjuvant radiotherapy (P<0.001). The proportions of 
very young women (aged <35 years) were similar in 
both treatment groups (35% vs 38%, respectively).
 The median follow-up time was 6.5 years (range, 
0.2-14.5 years). Twelve (10%) of the patients in the BCT 
group and eight (6%) having mastectomy developed 
in-breast recurrences or chest wall relapses, 
respectively. The 6-year local failure-free survival and 
loco-regional failure-free survival rates for the BCT 
versus MRM groups were 92% versus 93% (P=0.324; 
Fig a) and 89% versus 88% (P=0.721), respectively. Of 
the 12 patients with in-breast recurrences after BCT, 
three had simultaneous distant failures at the time 
of relapse; the remaining nine patients underwent 
salvage mastectomy but five developed subsequent 
distant failures. Only four (33%) patients with in-breast 
recurrences remained disease-free at last assessment. 
Of the eight patients with post-mastectomy chest wall 
recurrences, six had simultaneous distant failures; 
the remaining two (25%) underwent local excision 
and both remained disease-free at last assessment.
 The distant failure-free survival and overall 
TABLE 1. Clinical, pathological, and treatment characteristics of the 258 young 
Chinese patients with invasive breast cancers*
BCT 
(n=124)
MRM 
(n=134)
Total 
(n=258)
P value
Age (years)
Mean
Range
<35
35-40
36
24-40
43 (35%)
81 (65%)
36
28-40
51 (38%)
83 (62%)
36
24-40
94 (36%)
164 (64%)
0.813
Pathological size of invasive 
tumour (cm)
Mean
Range
1.9
0.2-4.6
2.4
0.3-5.0
2.2
0.2-5.0
<0.001
Pathological T classification†
T1
T2
79 (64%)
45 (36%)
51 (38%)
83 (62%)
130 (50%)
128 (50%) <0.001
Pathological N classification† 
Nx
N0
N1-3
3 (2%)
81 (65%)
40 (32%)
3 (2%)
57 (43%)
74 (55%)
6 (2%)
138 (53%)
114 (44%)
<0.001
Histological grade (for infiltrating 
ductal carcinoma only)
Grade 1
Grade 2
Grade 3
Unknown/not applicable
15 (12%)
42 (34%)
49 (40%)
18 (15%)
12 (9%)
50 (37%)
60 (45%)
12 (9%)
27 (10%)
92 (36%)
109 (42%)
30 (12%)
0.600
Resection margins
Clear (>2 mm)
Close (≤2 mm) 
Positive
92 (74%)
28 (23%)
4 (3%)
102 (76%)
29 (22%)
3 (2%)
194 (75%)
57 (22%)
7 (3%)
0.866
Hormonal receptor status
Positive
Negative
Unknown
90 (73%)
29 (23%)
5 (4%)
87 (65%)
38 (28%)
9 (7%)
177 (69%)
67 (26%)
14 (5%)
0.291
HER2 overexpression
Positive
Negative
Unknown
26 (21%)
81 (65%)
17 (14%)
33 (25%)
61 (46%)
40 (30%)
59 (23%)
142 (55%)
57 (22%)
0.093
Adjuvant radiotherapy
Yes
No
124‡ 
(100%)
0 (0%)
83
(62%)
51 (38%)
207
(80%)
51 (20%)
<0.001
Adjuvant or neoadjuvant 
chemotherapy‡
Yes
No
76 (61%)
48 (39%)
113 (84%)
21 (16%)
189 (73%)
69 (27%)
<0.001
Adjuvant tamoxifen
Yes
No
80 (65%)
44 (35%)
69 (51%) 
65 (49%)
149 (58%)
109 (42%)
0.034
* BCT denotes breast conservation treatment, and MRM modified radical mastectomy; 
because of rounding, not all percentages total 100
† UICC classification, 2002 edition; UICC, International Union Against Cancer
‡ Three patients had induction chemotherapy before breast-conserving surgery
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survival rates are shown in Figures b and c, respectively. 
Paradoxically, patients treated by BCT had better 6-
year distant failure-free survival (88% vs 71%, P=0.002) 
and overall survival (92% vs 81%, P=0.173) rates than 
those treated by MRM, though the difference in 
overall survival did not reach statistical significance.
 The independent impact on local recurrence 
and overall survival by the choice of surgical options 
and other potential risk factors studied further by 
univariate and multivariate analyses are shown in 
Tables 2 and 3. For the risk of local recurrence, only 
the resection margin status (hazard ratio [HR]=2.77, 
P=0.050) and the presence of peritumoural invasion 
(HR=3.01, P=0.038) were significant independent risk 
factors. For overall survival, nodal status (HR=3.91, 
P<0.001) was the only independent risk factor in 
multivariate analysis. The choice of surgical options 
(BCT vs MRM) had no apparent adverse impact on all 
the clinical outcome parameters analysed. There was 
also no apparent difference between the very young 
(aged <35 years) and young women (35-40 years) in 
terms of clinical outcomes.
Discussion
In Hong Kong, the proportion of young breast cancer 
patients is substantially higher than that in western 
countries. For example, between 2001 and 2005, 
women aged below 45 years accounted for 27% of all 
breast cancers in Hong Kong, whereas in the United 
States, only 12.5% occurred in patients aged 45 years 
or less.18,19 Young age is a well-recognised adverse 
factor for distant failure, and this feature has been 
incorporated into many practice guidelines dealing 
with decisions about systemic adjuvant therapies.17,20,21 
In addition, a higher risk of in-breast recurrences 
was also commonly observed in younger patients 
after BCT, although different reports used a range of 
cut-off ages (from 35 to 45 years).14-16 Compared with 
the often quoted in-breast recurrence rate of 1% 
per year, in this study the observed 8% local failure 
rate at 6 years after BCT was consistent with other 
reports of higher local recurrence rates in young 
women.14-16 Although in-breast recurrences after BCT 
are more readily salvageable and thought to have less 
adverse implications than post-mastectomy chest 
wall recurrence, its association with subsequent 
distant failure and poor survival is now increasingly 
Factor Univariate Multivariate
Hazard ratio
(95% CI)
P value Hazard ratio
(95% CI)
P value
Age <35 (vs 35-40) years 0.41
(0.14-1.23)
0.110 - -
BCT (vs MRM) 1.56
(0.64-3.83)
0.328 - -
T classification 
T2 (vs T1)
0.74
(0.30-1.82)
0.507 - -
N classification
≥N1 (vs N0)
1.27
(0.51-3.13)
0.610 - -
Histological grade
Grade 3 (vs grade 1-2)
1.98
(0.78-5.05)
0.151 - -
HER2 overexpression 2.60
(1.02-6.58)
0.045 - 0.650
Peritumoural vascular 
invasion
2.46
(0.91-6.63)
0.075 3.01
(1.06-8.54)
0.038
Negative hormonal 
receptors 
0.74 
(0.24-2.23)
0.587 - -
Close (≤2 mm)/positive 
final resection margins
2.72
(1.12-6.60)
0.028 2.77
(1.00-7.68)
0.050
TABLE 2. Univariate and multivariate analyses of potential risk factors for local 
recurrence*
* BCT denotes breast conservation treatment, MRM modified radical mastectomy, and CI 
confidence interval
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FIG.  (a) Local failure-free survival, (b) distant failure-free survival, and (c) overall survival rates of 258 young Chinese women treated by breast 
conservation treatment (BCT) or modified radical mastectomy (MRM)
BCT
MRM
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Factor Univariate Multivariate
Hazard ratio 
(95% CI)
P value Hazard ratio
(95% CI)
P value
Age <35 (vs 35-40) years 0.90
(0.48-1.69)
0.741 - -
BCT (vs MRM) 0.65
(0.35-1.21)
0.176 - -
T classification
T2 (vs T1)
2.07
(1.10-3.90)
0.025 - 0.399
N classification
≥N1 (vs N0)
3.91
(2.00-7.65)
<0.001 3.91
(2.00-7.65)
<0.001
Histological grade
Grade 3 (vs grade 1-2)
1.17
(0.63-2.17)
0.627 - -
HER2 overexpression 1.78
(0.88-3.61)
0.110 - -
Peritumoural vascular 
invasion
2.49
(1.29-4.78)
0.006 - 0.128
Negative hormonal 
receptors
0.79
(0.38-1.62)
0.516 - -
Close (≤2 mm)/positive 
final resection margins
1.34
(0.66-2.71)
0.418 - -
TABLE 3. Univariate and multivariate analyses of potential risk factors for overall 
survival*
* BCT denotes breast conservation treatment, MRM modified radical mastectomy, and CI 
confidence interval
recognised.16,22-25 Our previous report has also shown 
that in-breast recurrence is a highly significant 
independent risk factor for distant failure-free 
survival.6 However, whether in-breast recurrence 
is an indicator of more aggressive disease from 
the outset or a cause of subsequent distant failure 
remains controversial. In this study, although most 
young patients with in-breast recurrences had no 
evidence of distant failure at the time of relapse and 
successfully underwent salvage mastectomy, only 
four (33%) remained disease-free at last assessment, 
which is not much better than mastectomy patients 
with chest wall recurrences.
 In view of the higher local recurrence rates in 
young women after BCT and the adverse implications 
of in-breast recurrences, whether young women 
should be offered BCT remains controversial. Study 
from the Fox Chase Cancer Center26 suggested that 
patients aged below 35 years were not at higher risk of 
local recurrence when treated by BCT. This was true if 
an extensive intraductal component was absent and 
if margin proximity (<2 mm) was taken into account. 
In another recent study in young women27 examining 
whether MRM improves outcomes compared with 
BCT, outcomes were not statistically different by 
type of local treatment though overall outcomes 
were worse for the younger age-group. There was 
also no statistically significant difference in loco-
regional relapse-free survival, distant relapse-free 
survival, and breast cancer–specific survival rates 
at 10 years among women aged 20 to 39 years who 
were considered ‘ideal’ BCT candidates (tumour 
size ≤2 cm, pathologically negative axillary nodes, 
negative margins, and no reported DCIS). The 
authors concluded that young age alone should not 
be a contra-indication to BCT.27 In general, our study 
results support the above findings, both in terms of 
survival estimates by the Kaplan-Meier method and 
multivariate analyses by Cox’s regression.
 Although we have a relatively high proportion 
of young women with breast cancers in Hong 
Kong, studies focusing on outcomes are scarce. 
Being a retrospective study, our findings must be 
interpreted with caution, because of the imbalance 
of prognostic factors and bias in treatment selection, 
not to mention the relatively small total number of 
patients studied and the limited follow-up duration. 
For example, the paradoxically inferior outcome of 
mastectomy patients is likely related to the inclusion 
of more patients with positive nodes and/or larger 
breast primaries, which are well-known important 
prognostic factors. In addition, the presence or 
absence of an extensive intraductal component was 
often not clearly reported and so was not analysed 
in this study. The resection margin status after MRM 
and BCT may also have different implications and 
analysing this in a multivariate analysis may also 
complicate the interpretation. Our study result 
should not be interpreted as dismissing the adverse 
effect of young age for BCT; instead, what we have 
shown is that with the careful selection by surgeons, 
up to half of these young Hong Kong women can be 
offered BCT without jeopardising survival outcomes, 
and the in-breast recurrence risk rate is only slightly 
higher than that usually quoted. The paramount 
importance of good resection margins cannot be 
over-emphasised, which is particularly critical for 
younger women who have a higher tendency to 
local recurrences. If sufficient margins cannot be 
obtained without compromising cosmetic outcomes, 
mastectomy with or without reconstruction should 
be considered as an alternative.
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